Repligen (NASDAQ:RGEN – Get Free Report) and Bio-Rad Laboratories (NYSE:BIO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
Valuation & Earnings
This table compares Repligen and Bio-Rad Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $785.10 million | 13.24 | $48.89 million | $0.73 | 252.29 |
| Bio-Rad Laboratories | $2.59 billion | 3.77 | $759.90 million | $8.25 | 44.25 |
Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Repligen has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Repligen and Bio-Rad Laboratories, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 0 | 4 | 12 | 2 | 2.89 |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
Repligen presently has a consensus price target of $173.21, suggesting a potential downside of 5.95%. Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 5.96%. Given Repligen’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.
Profitability
This table compares Repligen and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | 5.29% | 5.30% | 3.79% |
| Bio-Rad Laboratories | 8.59% | 3.54% | 2.48% |
Institutional & Insider Ownership
97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Repligen beats Bio-Rad Laboratories on 10 of the 15 factors compared between the two stocks.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
